The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

Experts recommend regular screening to increase the chance of detecting prostate cancer early, when it is most treatable. (Dreamstime/TCA) Prostate cancer is one of the most common cancers in the ...

Former President Joe Biden's office confirmed on Sunday that he was diagnosed with an "aggressive form" of prostate cancer. "Last week, President Joe Biden was seen for a new finding of a prostate ...

When a team of doctors diagnosed former President Joe Biden with an aggressive form of prostate cancer last month, it cast the most commonly occurring cancer among men into the national spotlight. But ...

ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. ZetaMet™ was granted FDA Breakthrough Device Designation in 2021 and is in Phase 2a ...